Celiac Disease Overview

According to the World Gastroenterology Organization (WGO), Celiac disease also known as coeliac disease/non-tropical sprue or gluten-sensitive enteropathy, is defined as a chronic, multiple-organ small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. It is a serious autoimmune disorder where the ingestion of gluten leads to damage in the small intestine; it is not an allergy caused by gluten.

“Celiac Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Celiac Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years. Celiac Disease Key players such as – ImmunogenX, Inc., Amgen Inc., and others, are developing therapies for the Celiac Disease treatment 

• Celiac Disease Emerging therapies such as – AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.   
• In April 2021, ImmunogenX initiated a Phase II, single-center prospective, double blind, placebo controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.

Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Celiac Disease Pipeline Therapeutics Assessment

• Celiac Disease Assessment by Product Type
• Celiac Disease By Stage and Product Type
• Celiac Disease Assessment by Route of Administration
• Celiac Disease By Stage and Route of Administration
• Celiac Disease Assessment by Molecule Type
• Celiac Disease by Stage and Molecule Type

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for the Celiac Disease treatment are – Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Siemens AG, and Bayer AG, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, and others

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

• AMY02 : AMYRA Biotech AG
• EQ102 : Equillium Bio.
• DONQ52 : Chugai Pharmaceutical Co., Ltd.
• CALY-002 : Calypso Biotech
• Latiglutenase : ImmunogenX, Inc.
• Ordesekimab : Amgen Inc.

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
• Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies

Celiac Disease Pipeline Market Drivers

• Increasing prevalence of Celiac Disease  
• Increasing R&D activities
• No Approved Therapy

Celiac Disease Pipeline Market Barriers

• Limited patient awareness about the disease
• Poor Patient Compliance

Scope of Celiac Disease Pipeline Drug Insight    

• Coverage: Global
• Key Celiac Disease Companies: ImmunogenX, Inc., Amgen Inc., and others
• Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting